Ensitrelvir

Brand names: Xocova · Active ingredient: Ensitrelvir

In short: XOCOVA is indicated for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19.

Forms & strengthsTablets: white to light yellow-white, round tablets containing 125 mg of ensitrelvir, debossed with the Shionogi trademark () above the identifier code "711" on one side and with a "125" on the other side.
LabelShionogi Inc.
Label updatedJul 03, 2026

What is Ensitrelvir used for?

XOCOVA is indicated for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19.

Ensitrelvir dosage

Verify pregnancy status of females of reproductive potential prior to initiating XOCOVA .

The recommended dosage of XOCOVA in adults and adolescents 12 years of age and older is 375 mg (three 125-mg tablets taken together) orally on Day 1 and 125 mg (one 125-mg tablet) orally on Days 2 to 5 with or without food .

Begin XOCOVA as soon as possible and within 72 hours following contact with an individual who has COVID-19. The tablets should be taken at approximately the same time each day. If a dose of XOCOVA is missed, take the missed dose as soon as possible on the same day, and then take the next dose as scheduled the following day.

How to take Ensitrelvir — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Embryofetal Toxicity

Advise pregnant women and females of reproductive potential that XOCOVA may cause fetal harm. Advise females of reproductive potential to inform their healthcare providers of a known or suspected pregnancy. Advise females of reproductive potential to use effective contraception during use of XOCOVA and for 2 weeks after the final dose .

Verify Pregnancy Status Before Initiating XOCOVA

Inform patients that they need to verify pregnancy status prior to initiating XOCOVA [see Dosage and Administration (2.1), Warnings and Precautions (5.1), and Use in Specific Populations (8.1, 8.3)].

Drug Interactions

Advise patients that XOCOVA can interact with certain drugs and is contraindicated for use with certain drugs; therefore, advise patients to report to their healthcare provider the use of any prescription or non-prescription medication or herbal products . …

Warnings & precautions

Do not take this medicine if: XOCOVA is contraindicated in patients with a history of clinically significant hypersensitivity reactions to ensitrelvir or any other components of the product.

XOCOVA is contraindicated in patients taking drugs that are:

Primarily metabolized by CYP3A for which elevated concentrations may be associated with serious and/or life-threatening reactions and

Strong CYP3A inducers because they may significantly reduce ensitrelvir plasma concentrations, leading to the potential loss of virologic response .

Based on animal reproduction studies, XOCOVA may cause fetal harm when administered to a pregnant woman. In rabbits, embryofetal toxicity (including skeletal malformations and embryofetal lethality) was observed in rabbit offspring following exposure of pregnant rabbits to ensitrelvir at 7 times the human exposures at the recommended human dose (RHD). Likewise in rats, fetal growth retardation, low fetal body weight, skeletal variations, offspring lethality, low body weight in offspring, and retardation of morphological development were observed following exposure during gestation and lactation at exposures 9 times the human exposures at the RHD .

Advise pregnant women and females of reproductive potential that XOCOVA may cause fetal harm. Verify pregnancy status of females of reproductive potential prior to initiating XOCOVA. Advise females of reproductive potential to use effective contraception during XOCOVA use and for 2 weeks after the final dose .

XOCOVA is a strong CYP3A inhibitor and an inhibitor of P-gp and BCRP. In patients receiving or initiating medications metabolized by CYP3A or transported by P-gp or BCRP, XOCOVA may increase plasma concentrations of those medications and may potentially lead to severe, life-threatening, or fatal events from increased exposure of concomitant medications. …

Ensitrelvir side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Hypersensitivity reactions including anaphylaxis

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The overall safety profile of XOCOVA is based on data from 2,831 adults and adolescents exposed to the recommended dosage and duration of XOCOVA in controlled clinical trials.

Trial SCORPIO-PEP was a randomized, double-blind, placebo-controlled trial in which 1,190 subjects received oral XOCOVA (375 mg [Day 1]/125 mg [Days 2-5]) and 1,187 subjects received oral placebo (Days 1-5). The most common adverse events (regardless of causality) occurring in ≥1% of the XOCOVA group and at a greater frequency compared to placebo were headache (2.9% and 2.6%, respectively), diarrhea (1.7% and 1.3%, respectively), and cough (1.1% and 0.6%, respectively). The proportion of subjects who discontinued study intervention due to an adverse event was <0.1% in both the XOCOVA and placebo groups.

Laboratory Abnormalities:

Asymptomatic hemoglobin declines from baseline of >2 g/dL occurred in 3% of XOCOVA recipients versus 1% of placebo recipients.

The following adverse reactions have been identified during post approval use of XOCOVA outside of the United States. …

Drug interactions

Ensitrelvir is a strong inhibitor of CYP3A and an inhibitor of P-gp and BCRP. Co-administration of XOCOVA with drugs that are primarily metabolized by CYP3A or are transported by P-gp or BCRP may result in increased plasma concentrations of such drugs and increase the risk of adverse events [see Contraindications (4), Warnings and Precautions (5.2), Drug Interactions (7.3), and Clinical Pharmacology (12.3)]. For drugs that are CYP3A substrates and contraindicated with XOCOVA, initiation of XOCOVA should be considered only after careful evaluation of relevant clinical and pharmacokinetic factors related to the concomitant medication. In addition, re-initiation of contraindicated CYP3A substrates should be considered based on an assessment of the duration of CYP3A inhibition and patient‑specific considerations. Refer to individual drug prescribing information for additional information.

Ensitrelvir is a CYP3A substrate; therefore, drugs that induce CYP3A may decrease ensitrelvir plasma concentrations and reduce XOCOVA therapeutic effect . Therefore, use of XOCOVA with strong CYP3A4 inducers is contraindicated . No dose adjustment is recommended when XOCOVA is used concomitantly with moderate or weak CYP3A inducers . …

About this medicine

XOCOVA tablets contain ensitrelvir, a SARS-CoV-2 main protease (Mpro) inhibitor. Ensitrelvir is present as a 1:1 co-crystal with fumaric acid and has the following chemical name:

(6E)-6-[(6-Chloro-2-methyl-2H-indazol-5-yl)imino]-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-triazinane-2,4-dione monofumaric acid

The molecular formula is C22H17ClF3N9O2∙C4H4O4 and the molecular weight is 647.96.

The structural formula is:

Ensitrelvir fumaric acid is a white powder that is freely soluble in dimethyl sulfoxide; slightly soluble in acetone, ethanol, and methanol; and practically insoluble in water.

XOCOVA is provided as tablets for oral use containing 125 mg of ensitrelvir.

Inactive ingredients are colloidal silicon dioxide, croscarmellose sodium, hydroxypropyl cellulose, mannitol, microcrystalline cellulose, and magnesium stearate.

How it works: Ensitrelvir is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drug . …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 526acf60-abc3-2cc2-e063-6294a90affa6. Read the full official label on DailyMed.